Drug Profile


Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Breast cancer; Histiocytosis
  • Phase I/II Pancreatic cancer; Solid tumours

Most Recent Events

  • 20 Jul 2017 Exelixis and Genetech enter amendment to settle dispute regarding cobimetinib agreement
  • 20 Jul 2017 Roche plans the phase III IMspire170 trial for Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy, In-operable/Unresectable) in third quarter of 2017
  • 30 Jun 2017 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease) in USA (PO) (NCT03193190)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top